Shiseido (OTCMKTS:SSDOY) and Conduit Pharmaceuticals (NASDAQ:CDT) Critical Survey

Shiseido (OTCMKTS:SSDOY) and Conduit Pharmaceuticals (NASDAQ:CDT) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

This table compares Shiseido and Conduit Pharmaceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shiseido	$6.94 billion	1.80	$155.11 million	$0.17	184.35
Conduit Pharmaceuticals	N/A	N/A	-$540,000.00	N/A	N/A

Shiseido has higher revenue and earnings than Conduit Pharmaceuticals.

Volatility & Risk

Shiseido has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.

Profitability

This table compares Shiseido and Conduit Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shiseido	1.02%	1.51%	0.76%
Conduit Pharmaceuticals	N/A	N/A	-20.19%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Shiseido and Conduit Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shiseido	0	0	0	0	N/A
Conduit Pharmaceuticals	0	0	0	0	N/A

Insider & Institutional Ownership

0.0% of Shiseido shares are held by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. 23.5% of Conduit Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Shiseido beats Conduit Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Shiseido

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.